Atlas of Psychiatric Pharmacotherapy
Roni Shiloh, Rafael Stryjer, David J. Nutt, Abraham Weizman
Publisher: Taylor & Francis
ISBN: 1841842818
Pub Date:2006 2/e
Type: Hardback Book
Extent: 240 pages
Illustrations: 200
Building upon the success of the previous edition, this new text provides a comprehensive understanding of the mechanisms of action involved in psychiatric pharmacotherapy.
Using imaginative and colorful double-page spreads, this exceptional book presents state-of-the-art information on all the basic principles of psychiatric pharmacotherapy, abused substances, drug interactions, and treatment strategies.
Contents:
Introduction
1. Basic Principles of Psychiatric Pharmacotherapy
1.1 Principles of drug action ?presynaptic nerve
Main reactions relevant for psychiatric pharmacotherapy
1.2 Principles of drug action ?postsynaptic nerve
Main reactions relevant for psychiatric pharmacotherapy
1.3 Signal transduction (I)
G-protein complex and activation of second messengers
1.4 Signal transduction (II)
Activation of protein kinase and subsequent protein phosphorilation
1.5 Signal transduction (III)
Gene expression
1.6 Neurotransmitters (I)
Monoamines ?synthesis and degradation
1.7 Neurotransmitters (II)
Glutamate (excitatory) ?synthesis and degradation
1.8 Neurotransmitters (III)
gamma-aminobutyric acid (GABA; inhibitory) ?
synthesis and degradation
1.9 Vesicular monoamine transporter type 2 (VMAT-2)
Mode of action
1.10 Intracellular modifications following activation of various receptors (I)
Changes in intracellular compounds following activation of major receptors
1.11 Receptor-mediated psychiatric symptoms/syndromes
Assumed role of specific receptors in major psychiatric syndromes
1.12 Receptor/transporter-mediated `non-psychiatric?symptoms
Assumed role of specific receptors in protecting from-/inducing `non-psychiatric?symptoms
1.13 Drugs?pharmacokinetics
Main pathways of drug metabolism
1.14 Drug?pharmacokinetics
Major CYP450 enzymes responsible for metabolizing various `non-psychiatric?drugs
1.15 Drugs pharmacokinetics
Major `psychiatric drugs affecting the hepatic CYP450 enzymes
2. Antidepressants and mood stabilizers
2.1 Major depressive disorder - Depressive state ?no treatment
2.2 Antidepressant drugs
Schematic classification according to main mode of therapeutic action
2.3 Major depressive disorder - Cellular changes following antidepressant treatment
2.4 Antidepressant drugs
Recently developed antidepressants ?SNRIs
Recently developed antidepressants ?mirtazapine
Recently developed antidepressants ?escitalopram
2.5 Pindolol ?5HT1A- and beta-adrenergic antagonist
Supposed mode of accelerating and augmenting the antidepressant effect of SSRIs
2.6 Antidepressant drugs - Comparative affinities to various receptors/transporters
2.7 Antidepressant drugs - The main CYP450 hepatic enzymes responsible for metabolizing antidepressant drugs
2.8 Antidepressant drugs - Main adverse side effects (I) ?anticholinergic and central nervous system (CNS) effects
2.9 Antidepressant drugs - Main adverse side effects (II) ?gastrointestinal and cardiovascular effects
2.10 Antidepressant drugs - Comparative sexual side-effect profile
2.11 Antidepressant drugs - Effects of antidepressant drugs on various sleep parameters
2.12 Antidepressant drugs - Monoamine oxidase inhibitors
2.13 Antidepressant drugs - Potential future developments
2.14 Antimanic treatments - Supposed mechanism of action
2.15 Mood stabilizers - Lithium
2.16 Mood stabilizers - Carbamazepine
2.17 Mood stabilizers - Valproate
2.18 Mood stabilizers - Topiramate
2.19 Mood stabilizers - Lamotrigine
2.20 Mood stabilizers - Comparative profile
3. Anxiolytic drugs
3.1 Anxiolytics (I) - The `fear?network and the role of serotonin in suppressing anxiety
3.2 Anxiolytics (II) - Mechanism of anxiolytic action of various drugs
3.3 Anxiolytics (III) - New approache
推薦指數：
其他相關書藉
[ 
[ 